Ono’s just-announced purchase of Deciphera has put the tenosynovial giant cell tumor space under the spotlight and SynOx is making strides to stay at the head of the pack helped by significant financing.

With adalimumab biosimilar market share increasing in the US, AbbVie says revenue erosion is on its expected pace, driven mainly by discounts. Skyrizi, Rinvoq continue growth trajectories.

The US FDA approved Day One’s pediatric brain cancer drug Ojemda, ImmunityBio’s bladder cancer immunotherapy Anktiva, an uncomplicated UTI claim for Utility Therapeutics’ Pivya, which has a long history in Europe, and Pfizer’s hemophilia B gene therapy Beqvez.

The European Medicines Agency believes Idorsia’s Jeraygo should be approved for use in the EU at two different doses rather than just the one approved by the US Food and Drug Administration last month.